Protalix BioTherapeutics, Inc. (NYSE:PLX - Free Report) - Analysts at Zacks Small Cap reduced their FY2025 earnings per share (EPS) estimates for Protalix BioTherapeutics in a report released on Tuesday, March 18th. Zacks Small Cap analyst J. Vandermosten now forecasts that the company will earn $0.43 per share for the year, down from their prior forecast of $0.44. The consensus estimate for Protalix BioTherapeutics' current full-year earnings is $0.01 per share.
Other analysts have also issued research reports about the company. StockNews.com lowered Protalix BioTherapeutics from a "strong-buy" rating to a "buy" rating in a report on Thursday. HC Wainwright upped their price target on shares of Protalix BioTherapeutics from $10.00 to $15.00 and gave the company a "buy" rating in a report on Monday, February 3rd.
View Our Latest Analysis on Protalix BioTherapeutics
Protalix BioTherapeutics Stock Performance
Protalix BioTherapeutics stock traded up $0.11 during midday trading on Thursday, reaching $2.60. The company's stock had a trading volume of 999,675 shares, compared to its average volume of 435,665. The firm has a market capitalization of $202.89 million, a PE ratio of -20.00 and a beta of 0.72. Protalix BioTherapeutics has a fifty-two week low of $0.82 and a fifty-two week high of $2.76. The stock's 50 day simple moving average is $2.40 and its 200 day simple moving average is $1.77.
Hedge Funds Weigh In On Protalix BioTherapeutics
Hedge funds have recently bought and sold shares of the stock. GSA Capital Partners LLP lifted its holdings in Protalix BioTherapeutics by 8.5% in the 3rd quarter. GSA Capital Partners LLP now owns 435,213 shares of the company's stock valued at $444,000 after purchasing an additional 33,969 shares in the last quarter. XTX Topco Ltd purchased a new position in shares of Protalix BioTherapeutics during the 3rd quarter worth $36,000. Virtu Financial LLC acquired a new stake in shares of Protalix BioTherapeutics during the third quarter worth $44,000. Sanctuary Advisors LLC purchased a new stake in shares of Protalix BioTherapeutics in the third quarter valued at $38,000. Finally, PFG Investments LLC purchased a new stake in shares of Protalix BioTherapeutics in the fourth quarter valued at $39,000. Hedge funds and other institutional investors own 16.53% of the company's stock.
About Protalix BioTherapeutics
(
Get Free Report)
Protalix BioTherapeutics, Inc, a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.
Further Reading
Before you consider Protalix BioTherapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Protalix BioTherapeutics wasn't on the list.
While Protalix BioTherapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
